ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2155

Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink

Alicia Gayle1, Nils Schoof2, Margarida Alves2, Deborah Clarke3, Chris Poole1, Christina Raabe2, Prithwiraj Das1 and Toby Maher4, 1Boehringer Ingelheim Ltd., Bracknell, United Kingdom, 2Boehringer Ingelheim International GmbH, Ingelheim, Germany, 3Department of Medical Affairs, Boehringer Ingelheim Ltd., Bracknell, United Kingdom, 4University College London and Royal Brompton Hospital, London, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Clinical practice, cross-sectional studies, diagnosis, interstitial lung disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease that is characterised by fibroblast dysfunction and excess extracellular matrix deposition that leads to skin thickening and internal organ damage. Patients with SSc often develop interstitial lung disease (ILD) which is currently the leading cause of death. The burden of SSc in the UK is currently unknown. However, it is reported that a high proportion of patients present with advanced disease at diagnosis. The reasons for late diagnosis in SSc are not fully understood, although different routes to diagnosis have been associated with differences in survival. This study aimed to investigate patient characteristics related to first SSc diagnosis in hospital, compared to primary care.

Methods: We carried out a population-based cross-sectional study using data from the Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES). All adult patients with a diagnosis of SSc were identified using International Classification of Diseases-10-Clinical Modification diagnosis codes in hospital records and READ codes in primary care electronic records combined with an adapted version of the EULAR algorithm for defining SSc. Patients were classified into 3 groups: incident SSc, SSc with incident ILD (SSc-ILD), and SSc with other organ involvement (SSc-OOI). Source of diagnosis and patient characteristics were then described.

Results: The study included 606 individuals with incident diagnosis of SSc recorded in either CPRD or HES. Only 1% of patients had a diagnosis code in both primary care and secondary care records. 81% of the cohort were women and the average age at diagnosis was 61 (SD = 15). 20% of the cohort had SSc-ILD and 63% had SSc-OOI with an overlap of 15%. Patients first diagnosed with SSc in hospital presented higher rates of hospital visits and had a greater proportion of “red-flag” symptoms predictive of SSc (e.g. Raynaud’s or gastrointestinal reflux) prior to SSc diagnosis. Patients with an overlap of SSc-ILD and SSc-OOI tended to be overweight or obese.

Conclusion: Our results provide evidence of differences between patients diagnosed with SSc through UK primary care or secondary/tertiary care routes. These findings should inform the development of initiatives to improve earlier diagnosis of SSc.


Disclosure: A. Gayle, Boehringer Ingelheim, 3; N. Schoof, Boehringer Ingelheim, 3; M. Alves, Boehringer Ingelheim, 3; D. Clarke, Boehringer Ingelheim, 3; C. Poole, Boehringer Ingelheim, 3; C. Raabe, Boehringer Ingelheim, 3; P. Das, Boehringer Ingelheim, 3; T. Maher, GSK, 2, 5,UCB, 2, 5, 6,Boehringer Ingelheim, Astra Zeneca, Roche, Bayer, Biogen Idec, Cipla, Prometic, Sanumed, 5,Apellis, 1.

To cite this abstract in AMA style:

Gayle A, Schoof N, Alves M, Clarke D, Poole C, Raabe C, Das P, Maher T. Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/diagnosis-of-systemic-sclerosis-in-the-united-kingdom-an-observational-study-using-the-clinical-practice-research-datalink/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnosis-of-systemic-sclerosis-in-the-united-kingdom-an-observational-study-using-the-clinical-practice-research-datalink/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology